1 Min Read
* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis
* FDA grants breakthrough therapy designation to Pimavanserin for dementia-related psychosis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.